Circulation. 1998;97:628-629
(Circulation. 1998;97:628-629.)
© 1998 American Heart Association, Inc.
Angiogenic Therapy of the Human Heart
Judah Folkman, MD
From Children's Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Judah Folkman, MD, Children's Hospital, Harvard Medical School, Hunnewell 103, 300 Longwood Ave, Boston, MA 02115. (Circulation. 1998;97:628-629.)
Key Words: Editorials • angiogenesis • growth substances
The field of
angiogenesis research was initiated 27 years ago by a hypothesis that
tumors are angiogenesis-dependent.1 Shortly
thereafter, in the early 1970s, it became possible to passage vascular
endothelial cells in vitro for the first
time.2 Bioassays for angiogenesis were developed
subsequently throughout that decade. The early 1980s saw the
purification of the first angiogenic factors.3 4 5 6
By the mid-1980s, angiogenesis inhibitors began to be
discovered.7 8 9 Translation of these laboratory
findings to clinical application started in 1989, when interferon alfa
was first used for the treatment of life-threatening hemangiomas in
infants.10 11 12
Clinical applications of angiogenesis research are being pursued
along three general lines: (1) prognostic markers in cancer
patients,13 14 (2) antiangiogenic therapy (for
review, see Reference 1515 ), and (3) angiogenic therapy. The first
angiogenic therapy of ischemic vascular disease was the
administration of vascular endothelial growth factor
(VEGF)/vascular permeability factor to patients with severe
peripheral vascular disease in the lower
limbs.16
In a landmark paper, Schumacher and colleagues now report the first
angiogenic therapy of human coronary heart
disease.17 It is an important study, not only
because the authors describe how they produced their own recombinant
human fibroblast growth factor-1 (FGF-1, also called acidic fibroblast
growth factor) and tested it in vitro and in vivo but also because they
conducted a randomized controlled clinical trial. In 20 patients with
three-vessel coronary artery disease who underwent two or three
venous bypass grafts and one from the internal mammary artery, the
angiogenic protein FGF-1 was injected into the myocardium
close to . . . [Full Text of this Article]
This article has been cited by other articles:
|
|
|
|
 
P. Voisine, A. Rosinberg, J. J. Wykrzykowska, Y. Shamis, G. F. Wu, E. Appelbaum, J. Li, F. W. Sellke, D. Pinto, C. M. Gibson, et al.
Skin-derived microorgan autotransplantation as a novel approach for therapeutic angiogenesis
Am J Physiol Heart Circ Physiol,
January 1, 2008;
294(1):
H213 - H219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. U. Lee, J. J. Wykrzykowska, and R. J. Laham
Angiogenesis: Bench to Bedside, Have We Learned Anything?
Toxicol Pathol,
January 1, 2006;
34(1):
3 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.C Felmeden, A.D Blann, and G.Y.H Lip
Angiogenesis: basic pathophysiology and implications for disease
Eur. Heart J.,
April 1, 2003;
24(7):
586 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Su, J. Arakawa-Hoyt, and Y. W. Kan
Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model
PNAS,
July 9, 2002;
99(14):
9480 - 9485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Laham, N. A. Chronos, M. Pike, M. E. Leimbach, J. E. Udelson, J. D. Pearlman, R. I. Pettigrew, M. J. Whitehouse, C. Yoshizawa, and M. Simons
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
J. Am. Coll. Cardiol.,
December 1, 2000;
36(7):
2132 - 2139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Su, R. Lu, and Y. W. Kan
Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart
PNAS,
November 22, 2000;
(2000)
250488097.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. L. Meyerson, C. L. Skelly, M. A. Curi, and L. B. Schwartz
Gene Therapy for Cardiovascular Disease
Seminars in Cardiothoracic and Vascular Anesthesia,
November 1, 2000;
4(4):
289 - 300.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. E. Udelson, V. Dilsizian, R. J. Laham, N. Chronos, J. Vansant, M. Blais, J. R. Galt, M. Pike, C. Yoshizawa, and M. Simons
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
Circulation,
October 3, 2000;
102(14):
1605 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Pantely and J. M. Porter
Therapeutic angiogenesis: time for the next phase
J. Am. Coll. Cardiol.,
October 1, 2000;
36(4):
1245 - 1247.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Waltenberger, J. Lange, and A. Kranz
Vascular Endothelial Growth Factor-A-Induced Chemotaxis of Monocytes Is Attenuated in Patients With Diabetes Mellitus : A Potential Predictor for the Individual Capacity to Develop Collaterals
Circulation,
July 11, 2000;
102(2):
185 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kornowski, S. Fuchs, M. B. Leon, and S. E. Epstein
Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis
Circulation,
February 1, 2000;
101(4):
454 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Basile-Borgia, J. H Abel, and H. Mahloogi
Molecular advances in cardiac and cardiovascular disease
Perfusion,
March 1, 1999;
14(2):
89 - 99.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Verrier, S. Waxman, E. G. Lovett, and R. Moreno
Transatrial Access to the Normal Pericardial Space : A Novel Approach for Diagnostic Sampling, Pericardiocentesis, and Therapeutic Interventions
Circulation,
November 24, 1998;
98(21):
2331 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Topol and P. W. Serruys
Frontiers in Interventional Cardiology
Circulation,
October 27, 1998;
98(17):
1802 - 1820.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Su, R. Lu, and Y. W. Kan
Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart
PNAS,
December 5, 2000;
97(25):
13801 - 13806.
[Abstract]
[Full Text]
[PDF]
|
|
|
